SATC Satcon Technology Corp. (MM)

The Aurelius Consulting Group Launches Micro-Cap Newsletter: Highlights CardioTech International and Satcon Technology Corporation WINTER PARK, Fla., July 6 /PRNewswire/ -- The Aurelius Consulting Group, an internationally recognized investor relations firm, announced today the launch of a proprietary newsletter, The "Aurelius Micro-Cap Investor" (http://www.runonideas.com/aureliusinvestor.html). The newsletter, distributed electronically and through direct mail, targets Wall Street's micro-cap equity players, including individual investors, retail stock- brokers, fund-managers and analysts. Published bi-monthly, the June/July 2004 issue features two Boston based companies: Satcon Technology Corporation (NASDAQ:SATC) and CardioTech International (AMEX:CTE), both clients of the Aurelius Consulting Group. The president of the Aurelius Consulting Group, Dave Gentry, stated: "As evidenced by our track record and our references (see http://www.runonideas.com/references.asp; http://www.runonideas.com/casestudies.asp), we are known for our ability to attract long-term retail and institutional investors to previously undervalued, undiscovered companies. Our newsletter will play an important role in our comprehensive investor relations awareness programs." He added, "It is a pleasure to represent companies such as CardioTech International (CTE), the only company in the world in human clinical trials with an artificial coronary artery bypass graft, and Satcon Technology Corporation (SATC), a classic turn-around situation with strong revenue growth and a leader in the manufacturing and distribution of power conversion systems for alternative energy technologies." A spin-off of Polymedica Corporation (PLMD), CardioTech International (CTE) was founded by Dr. Michael Szycher, one of the inventors of the best- selling artificial heart, the Heart-Mate. Considered a world authority on polyurethanes (the material of which the coronary artery bypass graft is made), he has written five books on the subject and holds 17 patents. The Company's potential rocket ship product, the CardioPass, addresses a potential $1.5 billion market. The Company generated revenues of $21.7 million in fiscal 2004; maintains a strong cash position; is debt free, and is generating positive cash flow. The Aurelius network of client companies covers the following sectors: Consumer Finance, Business Services, Biotech, Medical Device, High-Tech, and Homeland Defense Semi-conductors and Mining. For a complete list of Aurelius companies go to: http://www.runonideas.com/. For more information Contact: Dave Gentry Aurelius Consulting Group, Inc. 225 S. Swoope Ave., Suite 214 Maitland, Florida 32751 (407) 644-4256 (800) 644-6297 http://www.runonideas.com/ This press release is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, we have not independently verified all the information contained herein. We receive compensation to act in an investor relations capacity for all clients mentioned herein. Also, we, from time to time, receive stock in compensation for our services from some, but not all of our clients. The large majority of the stock we receive as compensation is Rule 144 (restricted) stock, with a holding period of a minimum of 12 months. http://www.runonideas.com/aureliusinvestor.html http://www.runonideas.com/references.asp http://www.runonideas.com/casestudies.asp DATASOURCE: Aurelius Consulting Group, Inc. CONTACT: Dave Gentry, Aurelius Consulting Group, Inc., +1-407-644-4256, or +1-800-644-6297, or Web site: http://www.runonideas.com/

Copyright